Data from INVOKE-2, evaluating TREM2 agonist candidate AL002 in patients with early Alzheimerβs disease (AD...
--Participant baseline characteristics in INFRONT-3 suggest a representative study population that enables...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Subscribe to Ad free and enjoy an ad-free experience
Try Now
Keep the Ads